Slide 1: Virtual Investor Event: Long-Term Results from Phase 2b ORIGIN Study of Atacicept in IgAN
Exhibit 99.2 Virtual Investor Event to Discuss Long-Term Results from the Phase 2b ORIGIN Study of Atacicept in IgAN Presented at ASN Kidney Week 2024 October 28, 2024 © 2024 VERA THERAPEUTICS, INC.
Slide 2: Forward-looking statements
Forward-looking statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Company ). Statements contained in this presentation regarding matters, events or results that may occur in the future are “forward-looking statemen
Slide 3: Atacicept potentially best and first-in-class dual BAFF/APRIL B cell modulator in IgAN
Atacicept potentially best and first-in-class dual BAFF/APRIL B cell modulator in IgAN, with pipeline-in-a-product opportunity IgAN Potential Best-in-Class Indication Expansion Resourced for Potential Launch • eGFR normalization may suggest • B cell modulation represents a • Regulatory exclusivity e
Slide 4: Strong financial position
Strong financial position ~$384M ~54.8M Shares outstanding Cash, cash equivalents, (as of 8.5.24) and marketable securities (as of 6.30.24) 4 © 2024 VERA THERAPEUTICS, INC.
Slide 5: Vera optionality to expand in autoimmune kidney disease & beyond
Vera optionality to expand in autoimmune kidney disease & beyond US prevalence estimates ~230K Potential Future Indications 1-10 + ~70K Hematology ITP, AIHA, CAD, APS 1 ~160K Rheumatology Non-IgAN SLE, Sjogren’s, Long COVID autoimmune Neurology kidney disease MG pMN, FSGS, MCD and Metabolism Expande
Slide 6: Atacicept projected catalysts
Atacicept projected catalysts Catalyst 2024 2025 2026 Phase 3 primary endpoint cohort full enrollment 3Q Phase 2b 96-week results 4Q Phase 3 top-line results 2Q (IgAN) BLA submission 2H 1 Projected US launch Initiation (IgAN) Initial data available Initiation (IgAN, PMN, Initial data available FSGS,
Slide 7: Long-term Results From the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
Long-term Results From the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN 1 2 3 3 3 4 Jonathan Barratt, Sean Barbour, Robert Brenner, Kerry Cooper, Xuelian Wei, Necmi Eren, 5 6 7 8 9 10 Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Bart Maes, Richard Phoon, Harmeet Singh, 11 12 Vladimi
Slide 8: IgAN is a B-cell mediated disease with kidney pathology
IgAN is a B-cell mediated disease with kidney pathology B Cell Activation Formation of Circulating Immune Complexes Immune Complex Deposition Leading to Glomerulonephritis and Kidney Damage Autoantigen (Gd-IgA1) BAFF TACI B cell Glomerulus APRIL Autoantibody (anti-Gd-IgA1) 1 2 3 4 5 BAFF and APRIL a
Slide 9: Atacicept is a dual inhibitor of BAFF and APRIL
Atacicept is a dual inhibitor of BAFF and APRIL Rational drug design: native TACI receptor fused to Fc — fully humanized soluble fusion protein BAFF APRIL BAFF APRIL Atacicept 1 t =35 days 1/2 Kd Kd 2 2 1.45 nM 0.672 nM TACI TACI receptor receptor Fc domain B cell B cell of IgG1 Fc = fragment crysta
Slide 10: ORIGIN Phase 2b IgAN trial: Study design and objectives
ORIGIN Phase 2b IgAN trial: Study design and objectives Multinational, randomized, placebo-controlled trial of atacicept self-administered at home via weekly 1-mL SC injection Double-Blind Treatment OLE Placebo n=30 Atacicept 25 mg QW n=15 Atacicept 150 mg QW Atacicept 75 mg QW n=30 Atacicept 150 mg
Slide 11: Demographics and baseline characteristics
1 Demographics and baseline characteristics 2 Atacicept treated participants n=113 Age, median (range), y 37 (18, 67) Male sex, n (%) 67 (59) Race, n (%) White 59 (52) Asian 51 (45) Native Hawaiian or Other Pacific Islander 1 (1) Other/not reported 2 (2) 2 eGFR, mean ± SD, mL/min/1.73 m 62 ± 28 UPCR
Slide 12: Participant disposition through weeks
Participant disposition through 96 weeks 232 screened 116 failed screening Randomized 116 randomized and treated double-blind treatment period 1 1 82 atacicept 34 placebo 2 3 2 discontinued treatment 3 discontinued treatment Completed week 36 and entered OLE 80 (98%) 31 (91%) OLE period 111 entered
Slide 13: ORIGIN Phase 2b 36-week results consistent with disease modifying IgAN profile
ORIGIN Phase 2b 36-week results consistent with disease modifying IgAN profile Placebo Atacicept 150 mg Reduction in Gd-IgA1 Resolution of hematuria 15 0 -5% 0 -20 -7% -15 -40 -30 -60 -45 p<0.001 p<0.001 -80 -60 -80% -64% -75 -100 0 12 24 36 0 12 24 36 Week Week n= 33 33 33 29 22 22 22 19 n= 32 30 3
Slide 14: ORIGIN Phase 2b long-term results consistent with disease modifying IgAN profile
ORIGIN Phase 2b long-term results consistent with disease modifying IgAN profile Data from first dose of atacicept through 96 weeks Reduction in Gd-IgA1 Resolution of hematuria 0 0 -15 -20 -30 -40 -45 -60 -75% -60 -80 -66% -75 -100 0 12 24 36 48 60 72 96 0 12 24 36 48 60 72 84 96 Week from First Ata
Slide 15: Atacicept eGFR slope profile consistent with general population without kidney disease
Atacicept treated participants have an eGFR slope profile consistent with the general population without kidney disease 4 Slope, mL/min/y 0 Atacicept ~ -0.6 ~ -1 General population 1 estimate -4 IgAN natural history -8 including supportive 2 CKD therapy ~ -6 -12 0 12 24 36 48 60 72 84 96 Week This d
Slide 16: 2024 Draft KDIGO IgAN guidelines call for target eGFR slope ≤ -1 mL/min/year
2024 Draft KDIGO IgAN guidelines call for target eGFR slope ≤ -1 mL/min/year 1 % patients who will reach kidney failure 0 25 50 75 100 -0.1 0 0 2 2 1 1 -0.5 25 17 19 15 6 8 -1 56 40 38 40 23 16 -2 100 89 80 78 60 26 2 Endothelin receptor antagonist ~ -3 -3 100 100 100 91 85 46 3 4 SGLT2i , corticost
Slide 17: Atacicept generally well tolerated through weeks
Atacicept generally well tolerated through 96 weeks: OLE AE profile consistent with randomized period Double-Blind Open-Label Extension 1 Baseline to Week 36 Week 36 to 96 Placebo All Atacicept Atacicept 150 mg n=34 n=82 n=111 Participants, n (%) TEAEs 28 (82) 60 (73) 85 (77) Infections and infestat
Slide 18: Conclusions
Conclusions • Participants treated with atacicept for 96 weeks demonstrated sustained and substantial reductions in Gd-IgA1, hematuria and UPCR with long-term stabilization of eGFR • The cumulative favorable safety profile remains consistent with that observed during the randomized 36 weeks of ORIGI
Slide 19: Acknowledgments
Acknowledgments Thank you to all our ORIGIN Phase 2b study volunteers and their families and the ORIGIN investigators, study staff, and collaborators Australia R Francis, V Levidiotis, E Pedagogos, R Phoon, J Ryan Belgium A Bouquegneau, B Maes, M Speeckaert Canada S Barbour Czech Republic I Rychlik,
Slide 20: Scan to view manuscript
Scan to view manuscript Long-term Results From an Open-label Extension Study of Atacicept for the Treatment of IgA Nephropathy 1 2 3 3 3 4 Jonathan Barratt, Sean J. Barbour, Robert M. Brenner, Kerry Cooper, Xuelian Wei, Necmi Eren, 5 6-8 9 10 11,12 13 Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Ba
Slide 21: Atacicept projected catalysts
Atacicept projected catalysts Catalyst 2024 2025 2026 Phase 3 primary endpoint cohort full enrollment 3Q Phase 2b 96-week results 4Q Phase 3 top-line results 2Q (IgAN) BLA submission 2H 1 Projected US launch Initiation (IgAN) Initial data available Initiation (IgAN, PMN, Initial data available FSGS,
Slide 22: © 2024 VERA THERAPEUTICS, INC.
© 2024 VERA THERAPEUTICS, INC.